NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Intellia Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$11.58+0.16 (+1.40%)
Close on Oct 19, 2026
- Market cap
- $1.55B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
144M of 140M shares
Institutional holders
328
55 new, 28 sold out
Net institutional buying
34M
In Q2 2026
Insider trades, 12 months
1 buys · 17 sales
Net sold $737.64K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| State Street Corporation | 9,234,987 | 6.80% | 13G (passive) | Jun 30, 2026 |
| BlackRock, Inc. | 8,453,014 | 8.20% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Portfolio Management | 6,266,007 | 5.30% | 13G (passive) | Mar 31, 2026 |
| Vanguard Capital Management | 5,945,571 | 5.03% | 13G (passive) | Mar 31, 2026 |
| Contrarius Investment Management Ltd | 5,889,936 | 5.50% | 13G (passive) | Sep 30, 2025 |
| Catherine D. Wood | 14,207,324 | 12.27% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NTLA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| ARK Investment Management LLC | 16,875,684 | 12.04% | $285.54M | +2,366,437 | 1.85% |
| BlackRock, Inc. | 15,409,023 | 11.00% | $260.72M | +3,253,217 | 0.00% |
| State Street Corp | 9,234,987 | 6.59% | $156.26M | +2,312,311 | 0.00% |
| Vanguard Portfolio Management LLC | 7,332,401 | 5.23% | $124.06M | +1,109,076 | 0.01% |
| D. E. Shaw & Co., Inc. | 6,443,323 | 4.60% | $109.02M | +715,146 | 0.05% |
| Vanguard Capital Management LLC | 6,028,586 | 4.30% | $102.00M | +944,481 | 0.00% |
| Two Sigma Investments, LP | 5,235,348 | 3.74% | $88.58M | +529,447 | 0.06% |
| FMR LLC | 4,773,034 | 3.41% | $80.76M | +2,705,812 | 0.00% |
| Ra Capital Management, L.P. | 4,526,926 | 3.23% | $76.60M | New | 0.67% |
| Regeneron Pharmaceuticals, Inc. | 3,702,995 | 2.64% | $62.65M | – | 35.35% |
| Geode Capital Management, LLC | 3,631,061 | 2.59% | $61.45M | +779,589 | 0.00% |
| Arrowstreet Capital, Limited Partnership | 3,280,760 | 2.34% | $55.51M | +1,883,517 | 0.02% |
| Sumitomo Mitsui Trust Holdings, Inc. | 2,897,529 | 2.07% | $49.03M | +924,468 | 0.03% |
| Nikko Asset Management Americas, Inc. | 2,897,529 | 2.07% | $49.03M | +924,468 | 0.63% |
| Dimensional Fund Advisors LP | 2,602,944 | 1.86% | $44.04M | +284,834 | 0.01% |
| Goldman Sachs Group Inc | 2,264,471 | 1.62% | $38.31M | +636,230 | 0.00% |
| UBS Group AG | 2,152,912 | 1.54% | $36.43M | −536,574 | 0.00% |
| Voloridge Investment Management, LLC | 2,066,356 | 1.47% | $34.96M | +454,822 | 0.15% |
| Contrarius Group Holdings Ltd | 1,955,228 | 1.40% | $33.08M | +43,389 | 1.52% |
| Jupiter Asset Management Ltd | 1,849,507 | 1.32% | $31.29M | +68,444 | 0.16% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 328 | 144M | 100.0% | 55 / 140 | 81 / 28 | 38M | 5M |
| Q1 2026 | 304 | 111M | 78.9% | 62 / 128 | 63 / 46 | 30M | 10M |
| Q4 2025 | 293 | 104M | 74.4% | 67 / 98 | 87 / 48 | 21M | 21M |
| Q3 2025 | 284 | 105M | 74.7% | 45 / 102 | 79 / 39 | 17M | 13M |
| Q2 2025 | 281 | 100M | 71.5% | 42 / 111 | 88 / 53 | 14M | 15M |
| Q1 2025 | 295 | 101M | 72.4% | 51 / 94 | 96 / 46 | 12M | 9M |
| Q4 2024 | 294 | 99M | 70.9% | 64 / 127 | 68 / 49 | 25M | 18M |
| Q3 2024 | 284 | 94M | 67.0% | 43 / 112 | 86 / 47 | 19M | 7M |
| Q2 2024 | 291 | 91M | 64.8% | 48 / 114 | 88 / 37 | 8M | 14M |
| Q1 2024 | 284 | 97M | 69.3% | 37 / 116 | 88 / 42 | 15M | 6M |
| Q4 2023 | 293 | 88M | 63.1% | 48 / 123 | 78 / 36 | 12M | 4M |
| Q3 2023 | 285 | 80M | 57.3% | 34 / 120 | 66 / 38 | 6M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of NTLA | Value | % of fund | As of |
|---|---|---|---|---|---|
| ARK Innovation ETF | 9,987,315 | 7.13% | $106.66M | 1.92% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 5,756,463 | 4.11% | $97.40M | 0.91% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,286,200 | 3.06% | $72.52M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,524,614 | 2.52% | $59.64M | 0.07% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 3,106,242 | 2.22% | $52.56M | 0.03% | Jun 30, 2026 |
| ARK Genomic Revolution ETF | 2,667,062 | 1.90% | $28.48M | 1.83% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 1,914,833 | 1.37% | $26.94M | 0.51% | May 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,798,189 | 1.28% | $30.43M | 0.06% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,604,987 | 1.15% | $27.16M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,478,652 | 1.06% | $15.79M | 0.05% | Jul 31, 2026 |
| Select Pharmaceuticals Portfolio | 1,266,200 | 0.90% | $17.82M | 1.19% | May 31, 2026 |
| iShares Russell 2000 Value ETF | 1,264,620 | 0.90% | $21.40M | 0.15% | Jun 30, 2026 |
| iShares Biotechnology ETF | 938,715 | 0.67% | $15.88M | 0.17% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 827,498 | 0.59% | $14.00M | 0.12% | Jun 30, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 820,243 | 0.59% | $8.76M | 0.39% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| John M. Leonard | President and CEO, Director | 1,205,479 | 0.86% | Aug 24, 2026 |
| Edward J. Dulac III | EVP, Chief Financial Officer | 148,175 | 0.11% | Jul 24, 2026 |
| Michael P. Dube | VP, Chief Accounting Officer | 66,886 | 0.05% | Jul 6, 2026 |
| Birgit C. Schultes | EVP, Chief Scientific Officer | 137,733 | 0.10% | Mar 3, 2026 |
| James Basta | EVP, General Counsel | 156,794 | 0.11% | Mar 3, 2026 |
| David Lebwohl | EVP, Chief Medical Officer | 131,192 | 0.09% | Mar 3, 2026 |
| Eliana Clark | EVP, Chief Technical Officer | 93,864 | 0.07% | Mar 3, 2026 |
| Derek Hicks | EVP, Chief Business Officer | 59,878 | 0.04% | Jan 7, 2025 |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | 77,388 | 0.06% | Jan 7, 2025 |
| Brian Goff | Director | 32,609 | 0.02% | Jun 10, 2026 |
| Georgia Keresty | Director | 41,083 | 0.03% | Jun 10, 2026 |
| Muna Bhanji | Director | 36,403 | 0.03% | Jun 10, 2026 |
| Fred E. Cohen | Director | 216,653 | 0.15% | Jun 10, 2026 |
| Jesse Goodman | Director | 33,559 | 0.02% | Jun 10, 2026 |
| Frank Verwiel | Director | 35,148 | 0.03% | Jun 10, 2026 |
| William J. Chase | Director | 143,893 | 0.10% | Jun 10, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John M. Leonard President and CEO, Director | Aug 21, 2026 | Sale(10b5-1 plan) | −2,785 | $13.00 | $36.21K | 1,147,064 |
| John M. Leonard President and CEO, Director | Aug 20, 2026 | Sale(10b5-1 plan) | −19,890 | $12.60 | $250.61K | 1,149,849 |
| Edward J. Dulac III EVP, Chief Financial Officer | Jul 22, 2026 | Sale | −8,111 | $11.25 | $91.25K | 148,175 |
| Edward J. Dulac III EVP, Chief Financial Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −4,677 | $18.00 | $84.19K | 156,286 |
| Michael P. Dube VP, Chief Accounting Officer | Jul 1, 2026 | Sale | −2,641 | $16.78 | $44.32K | 66,886 |
| Fred E. Cohen Director | Jun 9, 2026 | Award | +9,200 | – | – | 216,653 |
| Jesse Goodman Director | Jun 9, 2026 | Award | +9,200 | – | – | 33,559 |
| Brian Goff Director | Jun 9, 2026 | Award | +9,200 | – | – | 32,609 |
| Georgia Keresty Director | Jun 9, 2026 | Award | +9,200 | – | – | 41,083 |
| Frank Verwiel Director | Jun 9, 2026 | Award | +9,200 | – | – | 35,148 |
| Muna Bhanji Director | Jun 9, 2026 | Award | +9,200 | – | – | 36,403 |
| William J. Chase Director | Jun 9, 2026 | Award | +9,200 | – | – | 143,893 |
| James Basta EVP, General Counsel | Mar 2, 2026 | Sale | −1,211 | $13.78 | $16.69K | 156,794 |
| Eliana Clark EVP, Chief Technical Officer | Mar 2, 2026 | Sale | −607 | $13.78 | $8.36K | 93,864 |
| Edward J. Dulac III EVP, Chief Financial Officer | Mar 1, 2026 | Award | +61,280 | – | – | 160,963 |
| John M. Leonard President and CEO, Director | Mar 1, 2026 | Award | +156,400 | – | – | 1,169,739 |
| Birgit C. Schultes EVP, Chief Scientific Officer | Mar 1, 2026 | Award | +39,200 | – | – | 137,733 |
| James Basta EVP, General Counsel | Mar 1, 2026 | Award | +46,080 | – | – | 158,005 |
| Eliana Clark EVP, Chief Technical Officer | Mar 1, 2026 | Award | +7,353 | – | – | 94,471 |
| Michael P. Dube VP, Chief Accounting Officer | Mar 1, 2026 | Award | +17,250 | – | – | 69,527 |
| David Lebwohl EVP, Chief Medical Officer | Mar 1, 2026 | Award | +9,943 | – | – | 131,192 |
| David Lebwohl EVP, Chief Medical Officer | Jan 5, 2026 | Sale | −11,903 | $9.21 | $109.63K | 121,249 |
| Michael P. Dube VP, Chief Accounting Officer | Jan 5, 2026 | Sale | −2,989 | $9.21 | $27.53K | 52,277 |
| Edward J. Dulac III EVP, Chief Financial Officer | Jan 5, 2026 | Sale | −6,379 | $9.21 | $58.75K | 99,683 |
| James Basta EVP, General Counsel | Jan 5, 2026 | Sale | −10,397 | $9.21 | $95.76K | 101,528 |
| John M. Leonard President and CEO, Director | Jan 5, 2026 | Sale | −34,146 | $9.21 | $314.48K | 1,013,339 |
| Fred E. Cohen Director | Jan 5, 2026 | Buy | +150,000 | $9.35 | $1.40M | 207,453 |
| Eliana Clark EVP, Chief Technical Officer | Jan 5, 2026 | Sale | −9,515 | $9.21 | $87.63K | 87,118 |
| Birgit C. Schultes EVP, Chief Scientific Officer | Jan 5, 2026 | Sale | −8,508 | $9.21 | $78.36K | 98,533 |
| John M. Leonard President and CEO, Director | Dec 12, 2025 | Option exercise | +8,557 | $6.83 | $58.44K | 1,047,485 |
| John M. Leonard President and CEO, Director | Dec 11, 2025 | Sale(10b5-1 plan) | −49,959 | $9.49 | $474.11K | 1,077,115 |
| John M. Leonard President and CEO, Director | Dec 11, 2025 | Sale(10b5-1 plan) | −32,832 | $9.47 | $310.92K | 1,044,283 |
| John M. Leonard President and CEO, Director | Dec 11, 2025 | Sale(10b5-1 plan) | −5,355 | $9.59 | $51.35K | 1,038,928 |
| John M. Leonard President and CEO, Director | Dec 11, 2025 | Option exercise | +49,959 | $6.83 | $341.22K | 1,127,074 |
| Michael P. Dube VP, Chief Accounting Officer | Oct 1, 2025 | Sale | −1,871 | $17.38 | $32.52K | 55,266 |
| Birgit C. Schultes EVP, Chief Scientific Officer | Oct 1, 2025 | Sale | −31 | $17.38 | $539 | 105,184 |
| William J. Chase Director | Aug 20, 2025 | Buy | +100,000 | $10.03 | $1.00M | 134,693 |
| Edward J. Dulac III EVP, Chief Financial Officer | Jul 23, 2025 | Sale | −7,462 | $14.02 | $104.62K | 106,062 |
| Michael P. Dube VP, Chief Accounting Officer | Jul 2, 2025 | Sale | −2,503 | $9.95 | $24.90K | 57,137 |
| Eliana Clark EVP, Chief Technical Officer | Jul 1, 2025 | Sale | −1,022 | $9.82 | $10.04K | 95,369 |
| Jesse Goodman Director | Jul 1, 2025 | Sale(10b5-1 plan) | −1,547 | $9.23 | $14.28K | 24,359 |
| Jesse Goodman Director | Jun 30, 2025 | Sale(10b5-1 plan) | −1,547 | $9.56 | $14.79K | 25,906 |
| Georgia Keresty Director | Jun 11, 2025 | Award | +8,000 | – | – | 31,883 |
| Fred E. Cohen Director | Jun 11, 2025 | Award | +8,000 | – | – | 57,453 |
| Jesse Goodman Director | Jun 11, 2025 | Award | +8,000 | – | – | 27,453 |
| Muna Bhanji Director | Jun 11, 2025 | Award | +8,000 | – | – | 27,203 |
| William J. Chase Director | Jun 11, 2025 | Award | +8,000 | – | – | 34,693 |
| Brian Goff Director | Jun 11, 2025 | Award | +8,000 | – | – | 23,409 |
| Frank Verwiel Director | Jun 11, 2025 | Award | +8,000 | – | – | 25,948 |
| Muna Bhanji Director | Apr 29, 2025 | Sale(10b5-1 plan) | −265 | $8.50 | $2.25K | 19,203 |
| James Basta EVP, General Counsel | Mar 4, 2025 | Sale | −2,572 | $8.99 | $23.12K | 111,925 |
| Eliana Clark EVP, Chief Technical Officer | Mar 4, 2025 | Sale | −679 | $8.99 | $6.10K | 95,369 |
| James Basta EVP, General Counsel | Mar 1, 2025 | Award | +40,000 | – | – | 114,497 |
| Edward J. Dulac III EVP, Chief Financial Officer | Mar 1, 2025 | Award | +47,200 | – | – | 113,524 |
| Eliana Clark EVP, Chief Technical Officer | Mar 1, 2025 | Award | +32,000 | – | – | 96,048 |
| John M. Leonard President and CEO, Director | Mar 1, 2025 | Award | +136,000 | – | – | 1,077,115 |
| Birgit C. Schultes EVP, Chief Scientific Officer | Mar 1, 2025 | Award | +37,600 | – | – | 105,215 |
| David Lebwohl EVP, Chief Medical Officer | Mar 1, 2025 | Award | +43,200 | – | – | 130,866 |
| Michael P. Dube VP, Chief Accounting Officer | Mar 1, 2025 | Award | +14,000 | – | – | 59,640 |
| Muna Bhanji Director | Jan 29, 2025 | Sale(10b5-1 plan) | −265 | $9.97 | $2.64K | 19,468 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Clark Eliana Officer | Oct 5, 2026 | 57,750 | $736.31K | Oct 5, 2026 | Stock Option Exercise |
| John M. Leonard Officer, Director | Aug 20, 2026 | 22,675 | $293.64K | Aug 20, 2026 | Stock Option Exercise |
| Dulac Edward Officer | Jul 2, 2026 | 4,677 | $80.63K | Jul 2, 2026 | Restricted Stock Units |
| John M. Leonard Officer, Director | Dec 11, 2025 | 88,146 | $822.40K | Dec 11, 2025 | Restricted Vesting |
| Laura Sepp-Lorenzino Officer | Jan 8, 2024 | 2,275 | $64.11K | Jan 8, 2024 | Restricted Stock Unit |
| F. Crowley John Former Director | Dec 7, 2023 | 32,791 | $506.70K | Dec 6, 2023 | Option Exercise |
| Bhanji Muna Director | Jul 31, 2023 | 265 | $11.22K | Jul 31, 2023 | Restricted Stock |
| Bhanji Muna Director | Jul 6, 2023 | 1,867 | $73.38K | Jul 6, 2023 | Restricted Stock |
| Clark Eliana Officer | Jun 20, 2023 | 5,000 | $225.00K | Jun 20, 2023 | Stock Option Exercise |